NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its quarterly earnings data on Monday, November, 4th. The company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History.

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals.

12 analysts have issued twelve-month price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $29.00 to $66.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $50.08 in the next year. This suggests that the stock has a possible downside of 8.8%. View Analyst Price Targets for Deciphera Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

Headlines about DCPH stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 2,670,000 shares, a decrease of 13.3% from the September 30th total of 3,080,000 shares. Based on an average daily volume of 850,700 shares, the days-to-cover ratio is presently 3.1 days. Currently, 9.3% of the shares of the stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Catalent (CTLT), Perrigo (PRGO), The Medicines (MDCO), Dr.Reddy's Laboratories (RDY) and Arrowhead Pharmaceuticals (ARWR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), Cytokinetics (CYTK), Eyepoint Pharmaceuticals (EYPT) and GW Pharmaceuticals PLC- (GWPH).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (9.37%), Millennium Management LLC (5.29%), Orbimed Advisors LLC (4.82%), State Street Corp (1.48%), Pictet Asset Management Ltd. (0.90%) and Point72 Asset Management L.P. (0.62%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Orbimed Advisors LLC, Emerald Advisers LLC, CIBC Asset Management Inc and Kornitzer Capital Management Inc. KS. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii and Thomas Patrick Kelly. View Insider Buying and Selling for Deciphera Pharmaceuticals.

DCPH stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Pictet Asset Management Ltd., State Street Corp, Point72 Asset Management L.P., Granite Point Capital Management L.P., Man Group plc, Voloridge Investment Management LLC and Barclays PLC. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $54.93.

Deciphera Pharmaceuticals has a market capitalization of $2.80 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]